AI is Not a Magic Bullet

AI cures disease only if the cures already are within a set we have measured, waiting for a better approach. One problem: they do not. Most of human biology has never been observed with detail and understanding sufficient to target a therapy. No amount of inference recovers data that was never collected. The need for AI in life sciences and drug discovery is indisputable. Of roughly ten thousand known human diseases, the large majority have no approved therapy at all; among rare diseases, the figure approaches ninety-five percent. Most approved drugs slow a disease rather than stop it. For the bulk of human illness, medicine offers management or nothing. Humans are systems, and the hardest diseases are within human systems and unsolved. The constraint is not intelligence. It is understanding the system.

The AI Molecule

Artificial intelligence is reducing the time and cost required to discover new drug candidates. New forms of late-stage capital are allowing better companies to stay independent longer. Direct-to-patient distribution is weakening Pharma’s control of the commercial channel. Together, these changes alter the architecture of biotechnology. The molecule is being separated from the old machine that used to deliver it. This is a structural change in how drugs are discovered, financed, developed, negotiated, and delivered. Biotech companies will build discovery systems, develop clinical evidence, control proprietary data, preserve financing options, and reach patients more directly.